Short answer
Monte Rosa Therapeutics, Inc. (GLUE) filed an 8-K current report with the SEC on May 7, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q1 2026 results announced for quarter ended March 31, 2026.
Monte Rosa Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 results announced for quarter ended March 31, 2026
- Full financial results furnished in Exhibit 99.1 for investor review
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Monte Rosa Therapeutics, Inc. 8-K filings
Get the next GLUE 8-K as it lands
Follow GLUE for push alerts, or ask the research agent what this filing means.